Um die volle Funktionalität der Webseite nutzen zu können, müssen Sie JavaScript in ihrem Browser aktivieren.

DAX19.390,04+0,87 %

Gold2.658,25+0,05 %

Öl (Brent)79,04-0,57 %

Dow Jones42.865,63+0,97 %

US Tech 10020.269,38+0,14 %

EUR/USD1,09242-0,12 %

Top 15 der gesamten Suchanfragen der letzten 7 Tage

Login

Aktie

ISIN: FR0010259150 WKN: A0ESMG Land Flagge FR

Frankreich

Zur Watchlist hinzufügen Zum Portfolio hinzufügen

Zum Portfolio hinzufügen

114,85

EUR

+0,13 %

+0,15 EUR

Letzter Kurs 13.10.24 Lang & Schwarz

Geldkurs

13.10.24

114,40

EUR

17 STK

Briefkurs

13.10.24

115,30

EUR

17 STK

Ipsen Aktie kaufen

Sparplan anlegen

Neueste Nachrichten

Ipsen - September 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital 09.10.24 · globenewswire · Ipsen
The Global Biopharma Community is Now Actively Partnering for BIO-Europe(R) 2024 08.10.24 · Accesswire · Bayer
Ipsen’s Kayfanda (odevixibat) approved in European Union for cholestatic pruritus in Alagille Syndrome, a rare liver disease 23.09.24 · globenewswire · Ipsen
Ipsen’s Iqirvo (elafibranor) approved in the European Union as first new treatment for primary biliary cholangitis in nearly a decade 20.09.24 · globenewswire · Ipsen
Final results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx in advanced neuroendocrine tumors 16.09.24 · globenewswire · Ipsen
Ipsen provides update on CONTACT-02 Phase III trial in metastatic castration-resistant prostate cancer following final overall survival analysis 15.09.24 · globenewswire · Ipsen
Ipsen - August 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital 04.09.24 · globenewswire · Ipsen
IPSEN - Buy-back programme - Art 5 of MAR - Week 32 - 2024 13.08.24 · globenewswire · Ipsen
IPSEN - Buy-back programme - Art 5 of MAR - Week 31 - 2024 06.08.24 · globenewswire · Ipsen
Ipsen - July 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital 05.08.24 · globenewswire · Ipsen
IPSEN - Buy-back programme - Art 5 of MAR - Week 30 - 2024 30.07.24 · globenewswire · Ipsen
Ipsen receives CHMP positive opinions for Iqirvo (elafibranor) in Primary Biliary Cholangitis and Kayfanda (odevixibat) in Alagille Syndrome, two rare cholestatic liver diseases 26.07.24 · globenewswire · Ipsen

1
2
3
4
5

Meistgelesen

7 Tage
30 Tage
12 Monate

The Global Biopharma Community is Now Actively Partnering for BIO-Europe(R) 2024 124 Leser
Ipsen - September 2024 - Monthly information relative to the total number of voting rights and ... 100 Leser

Final results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx in advanced ... 576 Leser
Ipsen’s Iqirvo (elafibranor) approved in the European Union as first new treatment for primary ... 420 Leser
Ipsen provides update on CONTACT-02 Phase III trial in metastatic castration-resistant prostate ... 184 Leser
The Global Biopharma Community is Now Actively Partnering for BIO-Europe(R) 2024 124 Leser
Ipsen’s Kayfanda (odevixibat) approved in European Union for cholestatic pruritus in Alagille ... 116 Leser
Ipsen - September 2024 - Monthly information relative to the total number of voting rights and ... 100 Leser

Final results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx in advanced ... 576 Leser
Ipsen’s Iqirvo (elafibranor) approved in the European Union as first new treatment for primary ... 420 Leser
Description of the regulatory framework of the share repurchase program proposed by the Board of ... 324 Leser
IPSEN - Buy-back programme - Art 5 of MAR - Week 31 - 2024 312 Leser
Ipsen receives CHMP positive opinions for Iqirvo (elafibranor) in Primary Biliary Cholangitis and ... 272 Leser
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid ... 264 Leser
Ipsen delivers solid sales growth in the first nine months of 2023 and confirms its full-year ... 252 Leser
Ipsen’s Onivyde regimen, a potential new standard-of-care first-line therapy in metastatic ... 244 Leser
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological ... 228 Leser
IPSEN - Buy-back programme - Art 5 of MAR - Week 32 - 2024 224 Leser